Signal
Regulatory Scrutiny Intensifies Following Reported Death Linked to Off-Label NAD+ Infusion Therapy
- Category
- · Policy · Global
- Date
- July 22, 2026
- Source
- OVUM
Summary
A fatal incident involving intravenous NAD+ therapy has triggered renewed debate over the safety of wellness clinics and compounders. This development arrives as the FDA evaluates the inclusion of NMN and related precursors on the list of prohibited compounding substances.
The action lands in Care Delivery and shifts the ground rules for operators, payers, and clinical pathways. Coverage, reimbursement, and go-to-market friction in this lane typically re-rate on this kind of move.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source